Compounds for the treatment of inflammatory disorders

1. A compound of the Formula (I):

or a pharmaceutically acceptable salt thereof, wherein:

ring A is phenyl which is substituted with —Y—R 1 and —Z—R 2 as shown;

X is —(C(R 3 ) 2 ) m —;

T is selected from the group consisting of

and

wherein T is substituted with one to four R 10 moieties;

U is absent;

V is absent;

Y is selected from the group consisting of a covalent bond, —(C(R 4 ) 2 ) n —, —N(R 4 )—, —C(O)N(R 4 )—, —N(R 4 )C(O)—, —N(R 4 )C(O)N(R 4 )—, —S(O) 2 N(R 4 )—, —N(R 4 )—S(O) 2 , —O—, —S—, —C(O)—, —S(O)—, and —S(O) 2 —;

Z is selected from the group consisting of a covalent bond, —(C(R 4 ) 2 ) n —, —N(R 4 )—, —C(O)N(R 4 )—, —N(R 4 )C(O)—, —N(R 4 )C(O)N(R 4 )—, —S(O) 2 N(R 4 )—, —N(R 4 )—S(O) 2 —, —O—, —S—, —C(O)—, —S(O)—, and —S(O) 2 —;

m is 1;

n is 1 to 3;

R 1 is selected from the group consisting of H, cyano, —C(O)OH, —C(O)O-alkyl, —C(O)NH 2 , —C(O)NH(alkyl), —C(O)N(alkyl) 2 , alkynyl, halogen, alkyl, cycloalkyl, haloalkyl, aryl, heteroaryl, and heterocyclyl, wherein when each of said cycloalkyl, heterocyclyl, aryl and heteroaryl contains two radicals on adjacent carbon atoms, said radicals may optionally be taken together with the carbon atoms to which they are attached to form a five- to eight-membered cycloalkyl, aryl, heterocyclyl or heteroaryl ring; wherein each of the R 1 alkyl, alkynyl, aryl, heteroaryl, and heterocyclyl, optionally with the five to eight-membered cycloalkyl, aryl, heterocyclyl or heteroaryl ring is unsubstituted or optionally independently substituted with one to four R 20 moieties which can be the same or different; with the proviso that when

Y is —N(R 4 )—, —S— or —O—, then R 1 is not halogen or cyano;

R 2 is selected from the group consisting of H, cyano, —C(O)OH, —C(O)O-alkyl, —C(O)NH 2 , —C(O)NH(alkyl), —C(O)N(alkyl) 2 , alkynyl, halogen, alkyl, cycloalkyl, haloalkyl, aryl, heteroaryl, and heterocyclyl, wherein when each of said cycloalkyl, heterocyclyl, aryl and heteroaryl contains two radicals on adjacent carbon atoms, said radicals may optionally be taken together with the carbon atoms to which they are attached to form a five- to eight-membered cycloalkyl, aryl, heterocyclyl or heteroaryl ring; wherein each of the R 2 alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl, optionally with the five, to eight-membered cycloalkyl, aryl, heterocyclyl or heteroaryl ring is unsubstituted or independently substituted with one to four R 20 moieties which can be the same or different; with the proviso that when

Z is —N(R 4 )—, —S— or —O—, then R 2 is not halogen or cyano;

each R 3 is H;

each R 4 is the same or different and is independently selected from the group consisting of H, alkyl, cycloalkyl, haloalkyl, hydroxy, -alkylcycloalkyl, -alkyl-N(alkyl) 2 , heterocyclyl, aryl, and heteroaryl, wherein when each of said cycloalkyl, heterocyclyl, aryl, and heteroaryl contains two radicals on adjacent carbon atoms, said radicals may be taken together with the carbon atoms to which they are attached to form a five- to eight-membered cycloalkyl, aryl, heterocyclyl or heteroaryl ring;

R 10 is selected from the group consisting of hydrogen, cyano, nitro, —C(R 4 )═N—OR 4 , —OR 4 , —SR 4 , —N(R 4 ) 2 , —S(O)R 4 , —S(O) 2 R 4 , —N(R 4 )S(O) 2 R 4 , —N(R 4 )—C(O)—R 4 , —N(R 4 )—C(O)—N(R 4 ) 2 , —N(R 4 )—C(O)—OR 4 , —OC(O)N(R 4 ) 2 , —C(O)N(R 4 )—S(O) 2 R 4 , —S(O) 2 N(R 4 )—C(O)—R 4 , —C(O)N(R 4 )C(O)R 4 , —C(O)N(R 4 )C(O)NR 4 , —S(O) 2 N(R 4 ) 2 , —N(R 4 )—C(═NR 4 )—N(R 4 ) 2 , —N(R 4 )—C(═N—CN)—N(R 4 ) 2 , -haloalkoxy, —C(O)OR 4 , —C(O)R 4 , —C(O)N(R 4 ) 2 , halogen, alkyl, haloalkyl, aryl, heteroaryl, heterocyclyl, and cycloalkyl, wherein each of the R 10 alkyl, aryl, heteroaryl, heterocyclyl, and cycloalkyl is unsubstituted or substituted with one to four R 30 moieties which can be the same or different;

or wherein two R 10 moieties, when attached to the same or adjacent carbon atoms may optionally be taken together with the carbon atom(s) to which they are attached to form a cycloalkyl, cycloalkenyl, heterocyclyl, aryl, or heteroaryl ring;

R 20 is selected from the group consisting of cyano, nitro, —C(R 4 )═N—OR 4 , —OR 4 , —SR 4 , —N(R 4 ) 2 , —S(O)R 4 , —S(O) 2 R 4 , —N(R 4 )S(O) 2 R 4 , —N(R 4 )—C(O)—R 4 , —N(R 4 )—C(O)—N(R 4 ) 2 —N(R 4 )—C(O)—OR 4 , —OC(O)N(R 4 ) 2 , —C(O)N(R 4 )—S(O) 2 R 4 , —S(O) 2 N(R 4 )—C(O)—R 4 , —C(O)N(R 4 )C(O)R 4 , —C(O)N(R 4 )C(O)NR 4 , —S(O) 2 N(R 4 ) 2 , —N(R 4 )—C(═NR 4 )—N(R 4 ) 2 , —N(R 4 )—C(═N—CN)—N(R 4 ) 2 , -haloalkoxy, —C(O)OR 4 , —C(O)R 4 , —C(O)N(R 4 ) 2 , halogen, alkyl, haloalkyl, aryl, heteroaryl, heterocyclyl, and cycloalkyl; wherein when each of said R 20 aryl, heteroaryl, heterocyclyl and cycloalkyl contains two radicals on adjacent carbon atoms, said radicals may optionally be taken together with the carbon atoms to which they are attached to form a five- to eight-membered cycloalkyl, aryl, heterocyclyl or heteroaryl ring; wherein each of said R 20 alkyl, aryl, heteroaryl, heterocyclyl, and cycloalkyl, optionally with said five- to eight-membered cycloalkyl, aryl, heterocyclyl or heteroaryl ring is unsubstituted or substituted with one to four moieties selected independently from the group consisting of alkyl, halo, haloalkyl, hydroxy, alkoxy, haloalkoxy, hydroxyalkyl, cyano, nitro, —NH 2 ,

—NH(alkyl), and —N(alkyl) 2 ;

or when two R 20 moieties when attached to the same or adjacent carbon atoms may optionally be taken together with the carbon atom(s) to which they are attached to form a cycloalkyl, cycloalkenyl, heterocyclyl, aryl, or heteroaryl ring;

R 30 is selected from the group consisting of cyano, nitro, —C(R 4 )═N—OR 4 , —SR 4 , —N(R 4 ) 2 , —S(O)R 4 , —S(O) 2 R 4 , —N(R 4 )S(O) 2 R 4 , —N(R 4 )—C(O)—R 4 , —N(R 4 )—C(O)—N(R 4 ) 2 —N(R 4 )—C(O)—OR 4 , —OC(O)N(R 4 ) 2 , —C(O)N(R 4 )—S(O) 2 R 4 , —S(O) 2 N(R 4 )—C(O)—R 4 , —C(O)N(R 4 )C(O)R 4 , —C(O)N(R 4 )C(O)NR 4 , —S(O) 2 N(R 4 ) 2 , —N(R 4 )—C(═NR 4 )—N(R 4 ) 2 , —N(R 4 )—C(═N—CN)—N(R 4 ) 2 , -haloalkoxy, —C(O)OR 4 , —C(O)R 4 , —C(O)N(R 4 ) 2 , halogen, alkyl, haloalkyl, aryl, heteroaryl, heterocyclyl, and cycloalkyl; wherein when each of said R 30 aryl, heteroaryl, heterocyclyl and cycloalkyl contains two radicals on adjacent carbon atoms, said radicals may optionally be taken together with the carbon atoms to which they are attached to form a five- to eight-membered cycloalkyl, aryl, heterocyclyl or heteroaryl ring; wherein each of said R 30 alkyl, aryl, heteroaryl, heterocyclyl, and cycloalkyl, optionally with said five- to eight-membered cycloalkyl, aryl, heterocyclyl or heteroaryl ring is unsubstituted or substituted with one to four moieties selected independently from the group consisting of alkyl, halo, haloalkyl, hydroxy, alkoxy, haloalkoxy, cyano, nitro, —NH 2 , —NH(alkyl), and —N(alkyl) 2 ;

or when two R 30 moieties when attached to the same or adjacent carbon atoms may optionally be taken together with the carbon atom(s) to which they are attached to form a cycloalkyl, cycloalkenyl, heterocyclyl, aryl, or heteroaryl ring;

with the proviso that T is substituted with at least one R 10 moiety selected from the group consisting of cyano, —C(O)OR 4 , —C(O)R 4 , —C(O)N(R 4 ) 2 , —C(O)N(R 4 )C(O)R 4 , —C(O)N(R 4 )C(O)NR 4 , —SR 4 , —S(O) 2 R 4 , —N(R 4 )—C(O)OR 4 , —OC(O)N(R 4 ) 2 , —N(R 4 )C(O)N(R 4 ) 2 , —N(R 4 )—C(O)—R 4 , —S(O) 2 N(R 4 ) 2 , —S(O) 2 N(R 4 )—C(O)—R 4 , —N(R 4 )—C(═NR 4 )—N(R 4 ) 2 , —N(R 4 )—C(═N—CN)—N(R 4 ) 2 , and —C(R 4 )═N—OR 4 , wherein each R 4 independently is selected from the group consisting of H, alkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, wherein when each of said R 4 cycloalkyl, heterocyclyl, aryl, and heteroaryl contains two radicals on adjacent carbon atoms, said radicals may optionally be taken together with the carbon atoms to which they are attached to form a five- to eight-membered aryl, heterocyclyl, heteroaryl or cycloalkyl ring.

2. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein said T is substituted with at least one R 10 moiety selected from the group consisting of cyano, —C(O)OR 4 , —C(O)R 4 , —C(O)N(R 4 ) 2 , and —C(R 4 )═N—OR 4 .

3. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein said T is substituted with at least one R 10 moiety that is cyano.

4. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein said T is substituted with at least one R 10 moiety that is —SR 4 .

5. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein said T is substituted with at least one R 10 moiety that is —S(O) 2 R 4 .

6. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein said T is substituted with at least one R 10 moiety that is —S(O) 2 N(R 4 ) 2 .

7. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein each of Y and Z is independently selected from the group consisting of a covalent bond and —O—.

8. The compound of claim 7 or a pharmaceutically acceptable salt thereof, wherein Y is —O— and Z is a covalent bond.

9. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein each of R 1 and R 2 is independently selected form the group consisting of H and alkyl.

10. The compound of claim 9 or a pharmaceutically acceptable salt thereof, wherein R 1 is alkyl and R 2 is H.

11. The compound of claim 10 or a pharmaceutically acceptable salt thereof, wherein R 1 is methyl.

12. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:

13. The compound of claim 12 or a pharmaceutically acceptable salt thereof wherein the compound is

14. The compound of claim 12 or a pharmaceutically acceptable salt thereof wherein the compound is

15. The compound of claim 12 or a pharmaceutically acceptable salt thereof wherein the compound is

16. The compound of claim 12 or a pharmaceutically acceptable salt thereof wherein the compound is

17. The compound of claim 12 or a pharmaceutically acceptable salt thereof wherein the compound is

18. A pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

19. A pharmaceutical composition comprising the compound of claim 12 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.